Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImmuneHunter

Financiado

Cerrado

Bioinformatics platform for profiling of health allowing early and accurate det...

Bioinformatics platform for profiling of health allowing early and accurate detection of multiple diseases simultaneously Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the relat... ver más

30/04/2018

PROTOBIOS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

PROTOBIOS OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-04-30

SMEInst-06-2016-2017: Accelerating market introduction of...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

PROTOBIOS

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DETECCIÓN Y PRONÓSTICO A MEDIO LARGO PLAZO EN... DETECCIÓN Y PRONÓSTICO A MEDIO LARGO PLAZO EN PACIENTES CON... 636K€ Cerrado

PTQ-12-05795 Predicción de enfermedades y fenotipos de pacientes mediante... 99K€ Cerrado

PTA2020-019567-I HIGH-THROUGHPUT IDENTIFICATION OF NOVEL BIOMARKERS AND MOLEC... 42K€ Cerrado

EQC2021-007365-P Plataforma de evaluación molecular proteica-genómica en comb... 1K€ Cerrado

CTQ2014-56777-R ESTRATEGIAS ANALITICAS DE IDENTIFICACION Y CARACTERIZACION D... 109K€ Cerrado

SiMBiT Single molecule bio electronic smart system array for clinic... 3M€ Cerrado

Duración del proyecto: 5 meses Fecha Inicio: 2017-10-31
Fecha Fin: 2018-04-30

Líder del proyecto

PROTOBIOS OU No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose these diseases as early and accurately as possible by analyzing biomarkers. However, the current analytical platforms have been unable to handle the huge amounts of data that need to be analysed for the discovery of new biomarkers, and as a result: (1) only a small number of new biomarkers have been discovered and (2) current routine diagnostic tests are able to provide only a very restricted overview of patient’s health status. Protobios applies a ground-breaking high-throughput antibody repertoire characterization technology Mimotope Variation Analysis (MVA) to discover new biomarkers, develop novel multiplexed diagnostics, and empower the discovery and development of therapeutics and vaccines. Compared to competing technologies, MVA is superior because (1) it allows to detect and distinguish many different disease signatures simultaneously and (2) the scalability and associated low cost of the MVA process make it applicable for frequent analysis, providing the additional advantage of establishing a robust health assessment tool. We have used MVA technology to provide clinical diagnostics' development services in a pilot format to a limited number of biotech companies and research institutions. We have witnessed growing demand and signed six-figure contracts for 2018. The key component of MVA is a sophisticated bioinformatics platform that enables molecular profiling of the immune response at an unprecedented resolution and accuracy. For full-scale market entry, we need to scale up the technical capability of the ICT platform so that the MVA service capacity grows by at least 100 times (corresponding to annual revenues of €20-25 million).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores